Outcome of Cervical Lymph Nodes Dissection for Thyroid Cancer with Nodal Metastases: A Southeast Asian 3-Year Experience
Table 2
Subgroup analysis of those who had recurrence in the 3-year follow-up period.
N = 43
Recurrence n (%)
OR (95% CI)
p
Yes, n=16 (37.2)
No, n= 27 (62.8)
Types of LND
Central LND n=8
2 (25.0)
6 (75.0)
0.569
Lateral LND n=15
7 (46.7)
8 (53.3)
-
Central + Lateral LND n=20
7 (35.0)
13 (65.0)
Histological types
Papillary thyroid cancer n=30
11 (36.7)
19 (63.3)
Follicular thyroid cancer n=7
2 (28.6)
5 (71.4)
-
0.755
Anaplastic thyroid cancer n=1
1 (100.0)
0 (0.0)
Medullary thyroid cancer n=5
2 (40.0)
3 (60.0)
TNM Staging
I, n=12
2 (16.7)
10 (83.3)
II, n=2
1 (50.0)
1 (50.0)
III, n=1
0 (0.0)
1 (100.0)
-
0.047
IVa, n=21
8 (38.1)
13 (61.9)
IVb, n=4
4 (100.0)
0 (0.00)
IVc, n=3
1 (33.3)
2 (66.7)
Tumour margin clear
Yes n=29
10 (34.5)
19 (65.5)
0.71 (0.19-2.59)
0.594
No n=14
6 (42.9)
8 (57.1)
LN margin clearance
Yes n = 28
11 (39.3)
17 (60.7)
1.29 (0.35-4.81)
0.700
No n=15
5 (33.3)
10 (66.7)
Radioiodine usage
Yes, n =30
13 (43.3)
17 (56.7)
2.55 (0.58-1.12)
0.307
No, n =13
3 (23.1)
10 (76.9)
Radiotherapy
Yes, n = 8
4 (50.0)
4 (50.0)
1.92 (0.41-9.01)
0.443
No, n = 35
12 (34.3)
23 (65.7)
Chemotherapy
Yes, n = 4
2 (50.0)
2 (50.0)
1.79 (0.23-14.08)
0.621
No, n = 39
14 (35.9)
25 (64.1)
LND, lymph node dissection; LN, lymph node; P value calculated using Fisher Exact Test. TNM staging is based on American Joint Committee for Cancer (AJCC) Cancer Staging Manual Seventh Edition [6].
